I have not bought yet. It was an interesting day for SGLB. One thing, it's definitely liquid! GPHBF, yeah, I think I'm gonna get some of that, too. HIGHLY speculative, risk abounds, not very liquid, but the most you can lose is 100% -- the upside potential (I emphasize: potential) is somewhere past Andromeda.
Dunno, but for the rest of 2015 I do expect sales to continue to grow at a good pace with a share price growing at the same or better pace.
Porter, interesting. Post-frenzy doldrums is a good time to buy if the fundamentals are there. It's a young industry, and there will no doubt be plenty of shake-out. I will take a closer look.
Slug, MNKD seems to have a great product that I imagine many will want. The company is deep in debt and spending fast, likely to have to raise cash, it seems. Everything depends on how fast they can ramp sales, which the three analysis links I read were less optimistic about than the current price would seem to support, IMO. It's definitely not under the radar. Too speculative for me right now, but worth watching.
Thanks Allen. The current PE is on the high side for me, and this is my play money, so I'm gonna pass on Rite Aid for now. Good luck.
Haven't done anything with my CONX proceeds yet. May add a bit more TBUFF, CYD and oil something if there's a price dip on the latter. Already long all of the above. Other ideas anyone?
Or maybe Virnetx is just happy to let the royalties and penalties continue to accumulate at whatever rate it turns out to be.
If I were to object at this point, which I am not, I would argue that the purpose of the strategic initiative was to enhance shareholder value, not to sell the company. While the agreed purchase price was fair and reasonable at the time it was made, it ultimately reduced shareholder value because of subsequent events, and the sale should have been terminated.
Unfortunately, that argument is based on speculation that a higher share price would be sustainable as the ebola crisis (and speculative fervor) abates, and I suspect Corgenix would be able to dispute that to the satisfaction of the court. Unless someone can provide reasonably hard evidence about higher future revenues, "That's speculation, your honor."
As I expected early on, the lawyers win again.
Shares gone, cash in @ .27/share. Having received none of the notifications, at least I got the money!
Not sure when Yahoo will take this board down, but I'll take this opportunity to say thanks and farewell, especially to the long-time contributors who feel like friends. (Is that pathetic or not? I think not.). It's been a good board. For most of the long-timers, I'd call CONX both a success and a disappointment. Decent return, coulda shoulda been better, especially over the last year.
Meanwhile, I'm recently in TBUFF. chucklk has been known to make an occasional appearance on that board, as well.
(P.S. GT, you have the best handle! 'Thanks' for the reminder that keeps things in perspective.)
I figured the price would hold at or above .60 after the earnings report. Wrong. Maybe some of the warrants that were exercised Monday at .50 are being sold off. Just guessing.
New, can you provide the specifics of that case and what it was based on?
As far as I can see, opposition to the Corgenix sale is driven by what the judge already rejected: the price. Apart from that, what is there to object to? Apart from the failed mailing, the process was apparently legal with no missteps, and national security is not likely to be an issue the judge will look at since there is a federal agency tasked with that, whether they do or not. Although it should still be thrown in the mix. You never know.
I just read it, too. Another thing that caught my eye was that they expect to be uplisted to the TSX within a few months (if I remember right), so that should provide some of the benefit you'd want from the higher share price of a reverse split. The transcript actually said 'uplifted', but I guess that works, too! :-)
I think Tribute wanted out of the R&D business, but marketing might fit. I suspect they have their hands full right now as they have recently taken on new products.
They should hold off on the reverse split. Price is bound to go up on its own over the next few quarters given the rapid growth in revenues.
Did anyone join the conf call? I was not able to.
Last year's report came out on 3/31. The much earlier timing of this year's report makes me suspect good news that they want to get out sooner rather than later. Plus a bunch of warrants exercised today -- the timing can't just be coincidental. My inference is those folks are expecting a boost in price and volume after earnings and the conference call. I added this morning.
Thanks. That was informative. Regarding .27 as a fair price, there's more to it than financials and book value, as demonstrated by share price every time news was announced about new funding or product approvals or Corgenix being mentioned by major news outlets. That should be included in considering shareholder value, I would think.
Back to my question: what do the attorneys get out of it in case of a win, and how will that affect Corgenix and, in turn, shareholder value?